OMEROS CORP
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
OMER$17.30-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(89,801) | $(125,457) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 6,459 | 8,067 |
| Loss on early extinguishment of 2026 Notes | 2,968 | — |
| Amortization of discount and issuance costs on convertible notes | 2,466 | 713 |
| Remeasurement on fair value of financial instruments | 680 | — |
| Depreciation and amortization | 729 | 649 |
| Remeasurement on OMIDRIA royalty obligation | (34,171) | (1,553) |
| Non-cash interest on OMIDRIA contract royalty asset | (11,521) | (12,824) |
| Remeasurement of OMIDRIA contract royalty asset | 16,383 | (7,384) |
| Amortization of premium and issuance costs on term debt | (4,727) | 488 |
| Accretion on U.S. government treasury bills, net | — | (4,295) |
| Changes in operating assets and liabilities: | ||
| OMIDRIA contract royalty asset | 24,404 | 29,586 |
| Prepaid expenses and other | 2,713 | 1,702 |
| Receivables | 831 | 1,790 |
| Accounts payable and accrued expense | 6,335 | (11,305) |
| Net cash used in operating activities | (76,252) | (119,823) |
| Investing activities: | ||
| Proceeds from the sale and maturities of investments | 71,500 | 969,221 |
| Purchases of investments | (18,458) | (921,819) |
| Purchases of property and equipment | (65) | (139) |
| Net cash provided by investing activities | 52,977 | 47,263 |
| Financing activities: | ||
| Proceeds from registered direct offering, net | 20,327 | — |
| Proceeds from issuance of common stock from the ATM facility, net | 15,292 | — |
| Proceeds upon exercise of stock options | 313 | 52 |
| Principal payments on OMIDRIA royalty obligation | (10,256) | (15,125) |
| Payment of debt issuance costs related to 2029 Notes | (2,837) | — |
| Payments on finance lease obligations | (569) | (446) |
| Proceeds from sale of future royalties | — | 115,525 |
| Cash paid to repurchase 2026 convertible senior notes | — | (21,179) |
| Repurchases of common stock | — | (11,851) |
| Net cash provided by financing activities | 22,270 | 66,976 |
| Net decrease in cash and cash equivalents | (1,005) | (5,584) |
| Cash and cash equivalents at beginning of period | 3,400 | 7,105 |
| Cash and cash equivalents at end of period | $2,395 | $1,521 |
| Supplemental cash flow information | ||
| Exchange of 2026 Notes for 2029 Notes | $70,785 | $— |
| Exchange of 2026 Notes for common stock | 10,000 | — |
| Cash paid for interest | 26,745 | 28,122 |
| Cash paid (received) for income taxes, net | 182 | (109) |
| Equipment acquired under finance lease | — | 509 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.